| Name | Title | Contact Details |
|---|
Connolly Strategies and Initiatives is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of prescription medicines for pets in the United States and Europe. It develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a potent and selective ghrelin agonist for the stimulation of appetite in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension to manage post-operative pain in cats and dogs following surgery. The company was founded in 2010 and is headquartered in Kansas City, Kansas.
Based in Chicago, BrightStar Care is a national private duty home care and medical staffing franchise with more than 280 locations that can provide medical and non-medical services to clients within their homes, as well as supplemental care staff to corporate clients. BrightStar Care professional nurses and caregivers deliver expert, compassionate, and personal care 24 hours a day, 7 days a week. Each BrightStar Care location is required to pursue Joint Commission Accreditation. BrightStar Care received The Joint Commission`s Enterprise Champion for Quality award in 2013, 2014, and 2015, and is committed to having each of its agencies comply with Joint Commission standards. BrightStar Care uses the nationally known patient satisfaction survey company Press Ganey to measure client satisfaction and is proud that nine out of 10 clients would recommend BrightStar Care to a friend or family member.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Turnpaugh Health and Wellness Center is a healthcare center that takes a whole body approach to health and wellness care, incorporating physical medicine, nutrition, emotional health, and ongoing support.